❌

Normal view

Lineage-specific pulmonary transcriptome landscape of coronavirus infection unveils universal immunotherapy for viral pneumonia

In the infection courses of different SARS-CoV-2 variants, disease outcomes and signatures were delineated by physiological changes, viral load, pathology, and pulmonary transcriptome analysis. This multi-dimensional landscape of disease outcomes and underlying mechanisms might provide important clues for immunotherapy of SARS-CoV-2 infection and pneumonia caused by other respiratory viruses.

TTPrint: Evidence-Grounded TTP Extraction via Diverge-then-Converge Verification

arXiv:2605.25836v1 Announce Type: cross Abstract: Extracting MITRE ATT&CK techniques from cyber threat intelligence (CTI) reports is an open-set, multi-label problem requiring both high recall (not missing techniques) and high precision (not hallucinating unsupported ones). Existing methods--rule-based, supervised, and LLM-based--struggle to achieve both: rule-based and supervised approaches lack generalizability across diverse attack descriptions, while LLM-based approaches that couple candidate generation and validation within a single inference step suffer from limited recall and precision simultaneously. We propose TTPrint, which addresses this challenge through a diverge-then-converge design inspired by how human analysts work: first extracting broadly, then verifying rigorously. In the divergent phase, reports are decomposed into atomic behaviors and candidate techniques are proposed broadly. A deterministic span localization stage then anchors each candidate to a specific evidence window in the source text. A convergent verification stage retains only candidates supported by both the localized evidence and the authoritative MITRE definition. We contribute two evaluation resources--a cleaned TRAM benchmark (TRAM-Clean) and a new annotated dataset (TTPrint-Bench)--to address known annotation noise in existing benchmarks and elevate the task to document-level TTP extraction. On TRAM-Clean and TTPrint-Bench, TTPrint achieves 76.48% and 87.39% macro-F1 respectively, outperforming the leading baseline by 63.5% and 29.4%. A multi-backbone analysis across six LLMs and a threshold sensitivity study further demonstrate generalizability across model choices and provide practical guidance for parameter selection.

Multi-omics analysis reveals AR as a potential prognostic factor and immune-related therapeutic target in gastric cancer

Biochem Biophys Rep. 2026 Mar 16;46:102537. doi: 10.1016/j.bbrep.2026.102537. eCollection 2026 Jun.

ABSTRACT

BACKGROUND: Although studies have shown that the androgen receptor (AR) is associated with tumor progression and malignant regulation, its role in the tumor immune microenvironment and predictive value for prognosis and immunotherapy response in various cancer types have not been systematically analyzed.

METHODS: In this paper, multi-omics techniques was used to analyze AR comprehensively.

RESULTS: A comprehensive pan-cancer analysis revealed that the AR was expressed in a variety of tumors, especially as a risk factor for poor prognosis in gastric cancer. In addition, gene set enrichment analysis showed that the AR promotes cell proliferation and tumor cell invasion and regulates anti-tumor response. Immune score, immune cell infiltration, and anticancer immune cycle analysis showed that high AR levels were correlated with low infiltration of CD4+ T cells and NKT cells, high infiltration of Th2 cells and MDSCs, negatively correlated with antigen-presenting molecules, and positively correlated with various immune-negative regulatory molecules. Single-cell sequencing highlighted the heterogeneous expression of ARs in different cell types, particularly in epithelial cells, where high AR levels were associated with the enhanced activity of tumor-promoting pathways.

CONCLUSIONS: In conclusion, this study highlights the potential of the AR as a novel biomarker for gastric cancer prognosis and immunotherapy efficacy, expanding its applicability in the development of new antitumor drugs.

PMID:41890218 | PMC:PMC13014673 | DOI:10.1016/j.bbrep.2026.102537

❌